DRUG NASDAQ
Credit Risk of going bust: lower than 92% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Total debt $47K against a stock market value of $504.0M.
Distance to default 15.74 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $23K (short-term plus half of long-term), stock volatility 62.4%; Altman Z'' 132.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York, NY 10013
US
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Companyâs BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cormorant Asset Mana | S-Sale | 109,331 | $89.50 | 2026-04-28 |
| Cormorant Asset Mana | P-Purchase | 184,331 | $21.70 | 2024-11-04 |
| Cormorant Asset Mana | P-Purchase | 3,107 | $25.22 | 2024-10-16 |
| Cormorant Asset Mana | P-Purchase | 7,150 | $24.03 | 2024-10-16 |
| Cormorant Asset Mana | P-Purchase | 39,743 | $23.21 | 2024-10-16 |